| Name | Title | Contact Details |
|---|
Praestan Health is a new health technology company that is building a precision-guided suite of health and wellbeing applications to support practitioners and individuals in efficient, effective, and sustainable health behavior change.
A Mission to Improve Healthcare. Mitesco, Inc. (OTCQB: MITI) is a public, development stage company whose mission is to acquire and implement technologies and services to improve the quality of care, reduce cost, and enhance consumer convenience. We are focused on developing a portfolio of companies that provide healthcare technology solutions and the team is adept at deal structures supportive of long term organizational value. The holding company structure facilitates profitable growth and enables acquired business to focus on scale. The MITI portfolio of companies will apply leading-edge solutions that emphasize stakeholder value and are based upon sector trends.
The New York Genome Center (NYGC) is at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations are united in this unprecedented collaboration of technology, science, and medicine. We implement advanced genomic research, and integrate our findings with world-class technologies and physician-scientists in order to help solve diseases. We harness the diversity of New York`s institutions and people to drive scientific discoveries that will vastly improve clinical care — ethically, equitably and urgently. We advocate and educate, sharing our findings with the global scientific, medical and thought leadership communities to broaden the reach of the New York Genome Center to help patients in every corner of the world. We create synergies through collaboration to continually innovate and advance our vision.
We are pursuing FDA approval of psychedelic therapies to heal individual mental health and strengthen communities. We plan to build a portfolio of plant-identical compounds. Our first compound in development is mescaline.
DNA2.0 is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Menlo Park, CA. To find more information about DNA2.0, please visit www.dnatwopointo.com